Dawn of a New Era: Targeting the Neuromuscular Root Cause of OSA With Oral Pharmacotherapy
- This event has passed.
November 18, 2025 @ 7:30 pm - 8:30 pm EST
Learning Objectives:
- Review the significant burden of OSA and the unmet treatment needs of people living with OSA.
- Educate on OSA pathophysiology and the link between pathophysiology, chronic intermittent hypoxia, and the OSA sequelae.
- Explain how the investigational AD109 drug targets neuromuscular dysfunction, including what has been learned about its mechanism of action (MOA).
- Present AD109 clinical data to illustrate its potential in addressing this unmet need.